Esketamine combined with pregabalin on acute postoperative pain in patients undergoing resection of spinal neoplasms: study protocol for a randomized controlled trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
25 Feb 2023
Historique:
received: 01 05 2022
accepted: 17 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

Perioperative pain management is one of the most challenging issues for patients with spinal neoplasms. Inadequate postoperative analgesia usually leads to severe postsurgical pain, which could cause patients to suffer from many other related complications. Meanwhile, there is no appropriate analgesic strategy for patients with spinal neoplasms. This is a protocol for a randomized double-blind controlled trial to evaluate the effect of esketamine combined with pregabalin on postsurgical pain in spinal surgery. Patients aged 18 to 65 years scheduled for spinal neoplasm resection will be randomly allocated into the combined and control groups in a 1:1 ratio. In the combined group, esketamine will be given during the during the surgery procedure until 48-h postoperative period, and pregabalin will be taken from 2 h before the surgery to 2 weeks postoperatively. The control group will receive normal saline and placebo capsules at the same time points. Both groups received a background analgesic regimen by using patient-controlled intravenous analgesia (containing 100 μg sufentanil and 16 mg ondansetron) until 2 days after surgery. To ensure the accuracy and reliability of this trial, all the researchers and patients will be blinded until the completion of this study. The primary outcome will be the proportion of patients with acute moderate-to-severe postsurgical pain (visual analog scale, VAS ≥ 40, range: 0-100, with 0, no pain; 100, the worst pain) during the 48-h postoperative period. The secondary outcomes will include the maximal VAS scores (when the patients felt the most intense pain over the last 24 h before being interviewed) at 0-2 h, 2-24 h, 24-48 h, and 48-72 h after leaving the operating room and 24 h before discharge; the incidence of acute moderate-to-severe postsurgical pain at each other time point; chronic postsurgical pain assessment; neuropathic pain assessment; and the incidence of drug-related adverse events and other postoperative complications, such as postoperative delirium and postoperative nausea and vomiting (PONV). The aim of this study was to evaluate the effect of esketamine combined with pregabalin on acute postsurgical pain in patients undergoing resection of spinal neoplasms. The safety of this perioperative pain management strategy will also be examined. ClinicalTrials.gov NCT05096468. Registered on October 27, 2021.

Sections du résumé

BACKGROUND BACKGROUND
Perioperative pain management is one of the most challenging issues for patients with spinal neoplasms. Inadequate postoperative analgesia usually leads to severe postsurgical pain, which could cause patients to suffer from many other related complications. Meanwhile, there is no appropriate analgesic strategy for patients with spinal neoplasms.
METHODS/DESIGN METHODS
This is a protocol for a randomized double-blind controlled trial to evaluate the effect of esketamine combined with pregabalin on postsurgical pain in spinal surgery. Patients aged 18 to 65 years scheduled for spinal neoplasm resection will be randomly allocated into the combined and control groups in a 1:1 ratio. In the combined group, esketamine will be given during the during the surgery procedure until 48-h postoperative period, and pregabalin will be taken from 2 h before the surgery to 2 weeks postoperatively. The control group will receive normal saline and placebo capsules at the same time points. Both groups received a background analgesic regimen by using patient-controlled intravenous analgesia (containing 100 μg sufentanil and 16 mg ondansetron) until 2 days after surgery. To ensure the accuracy and reliability of this trial, all the researchers and patients will be blinded until the completion of this study. The primary outcome will be the proportion of patients with acute moderate-to-severe postsurgical pain (visual analog scale, VAS ≥ 40, range: 0-100, with 0, no pain; 100, the worst pain) during the 48-h postoperative period. The secondary outcomes will include the maximal VAS scores (when the patients felt the most intense pain over the last 24 h before being interviewed) at 0-2 h, 2-24 h, 24-48 h, and 48-72 h after leaving the operating room and 24 h before discharge; the incidence of acute moderate-to-severe postsurgical pain at each other time point; chronic postsurgical pain assessment; neuropathic pain assessment; and the incidence of drug-related adverse events and other postoperative complications, such as postoperative delirium and postoperative nausea and vomiting (PONV).
DISCUSSION CONCLUSIONS
The aim of this study was to evaluate the effect of esketamine combined with pregabalin on acute postsurgical pain in patients undergoing resection of spinal neoplasms. The safety of this perioperative pain management strategy will also be examined.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT05096468. Registered on October 27, 2021.

Identifiants

pubmed: 36841794
doi: 10.1186/s13063-023-07178-3
pii: 10.1186/s13063-023-07178-3
pmc: PMC9960454
doi:

Substances chimiques

Pregabalin 55JG375S6M
Esketamine 50LFG02TXD
Analgesics 0

Banques de données

ClinicalTrials.gov
['NCT05096468']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

144

Subventions

Organisme : Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
ID : ZYLX201708; DFL20180502
Organisme : Beijing Municipal Science and Technology Commission
ID : Z19110700660000, Z191100006619067

Informations de copyright

© 2023. The Author(s).

Références

Medicine (Baltimore). 2017 Sep;96(37):e8031
pubmed: 28906391
Anesthesiology. 2019 Jul;131(1):119-131
pubmed: 31149930
Clin J Pain. 2019 Mar;35(3):272-278
pubmed: 30499836
Reg Anesth Pain Med. 2018 Jul;43(5):456-466
pubmed: 29870457
J Pain. 2016 Feb;17(2):131-57
pubmed: 26827847
Cochrane Database Syst Rev. 2019 Jan 23;1:CD007076
pubmed: 30673120
Medicine (Baltimore). 2017 Mar;96(11):e6129
pubmed: 28296725
Cochrane Database Syst Rev. 2013 Jul 24;(7):CD008307
pubmed: 23881791
JAMA Intern Med. 2017 Aug 1;177(8):1146-1153
pubmed: 28586818
Mayo Clin Proc. 2016 Jul;91(7):955-70
pubmed: 27344405
Cochrane Database Syst Rev. 2018 Dec 20;12:CD012033
pubmed: 30570761
J Pain Res. 2017 May 09;10:1071-1078
pubmed: 28533695
Pak J Med Sci. 2015 Jul-Aug;31(4):833-6
pubmed: 26430413
Anesthesiology. 2018 Sep;129(3):590-607
pubmed: 29738328
Anesthesiology. 2020 Aug;133(2):265-279
pubmed: 32667154
J Clin Anesth. 2021 Feb;68:110071
pubmed: 33007645
JAMA Surg. 2018 Apr 1;153(4):303-311
pubmed: 29238824
Psychol Med. 2014 Mar;44(4):697-706
pubmed: 23822897

Auteurs

Wanchen Sun (W)

Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070.

Juan Wang (J)

Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070.

Jing Wang (J)

Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070.

Jingyi Fan (J)

Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070.

Yang Zhou (Y)

Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070.

Yunzhen Wang (Y)

Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070.

Ruquan Han (R)

Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, No. 119, Southwest 4th Ring Road, Fengtai District, Beijing, People's Republic of China, 100070. ruquan.han@ccmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH